Drug Profile
Fibrin sealant - OMRIX
Alternative Names: AdhexilLatest Information Update: 12 Jan 2022
Price :
$50
*
At a glance
- Originator OMRIX Biopharmaceuticals
- Class Antihaemorrhagics; Blood coagulation factors; Blood proteins; Serine endopeptidases
- Mechanism of Action Fibrinogen replacements; Thrombin replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Post-surgical adhesions
Most Recent Events
- 01 Oct 2015 No recent reports of development identified - Phase-III for Post-surgical adhesions in Russia, Mexico, European Union and USA (Topical)
- 30 Dec 2008 OMRIX Biopharmaceuticals has been acquired by Johnson and Johnson
- 25 Oct 2007 Phase I/II clinical trials in Post-surgical adhesions in European Union (Topical)